5月29日，爱尔康(Alcon)公司宣布，美国FDA批准其"first-in-class"眼药水Tryptyr 0.003%眼药水上市，用于治疗干眼症(DED)。当日爱尔康股价收涨1.14%， 表现较为平淡，但远在大洋彼岸的港股兆科眼科-B(06622)却在当日大幅收涨了19.21%，而这也不过是这家公司此轮股价翻倍涨幅行情中的一个"小插曲"。 智通财经APP观察到，近两个月来，AH两地医药板块上涨明显，7成股票股价上涨，超过20家药企股价实现翻倍增长，兆科眼科便是其中之一。 4月9日，兆科眼科股价受到恒指大盘震荡影响触底1.30港元，在此之后公司股价开启一轮波动上涨行情，6月5日盘中，公司最高股价达到3.22港元。也就是 说，近2个月内，兆科眼科股价最大涨幅达到147.69%。 去年2月，兆科眼科股价因其阿托品NVK002未获FDA审批而出现跳水，收跌28.09%，而此次公司股价站上高点也与FDA有关。 6月4日，兆科眼科发布公告，美国FDA已批准公司就环孢素眼用凝胶(公司核心产品之一，前称环孢素A眼凝胶)用于治疗中重度干眼症作出的新药临床试验 申请。该项即将进行的研究将为一项第三期、多中心、随机、双盲、活 ...

ANNUAL 年 2024 報 REPORT CONTENTS 目 錄 Corporation Information 2 公司資料 Chairman and CEO Statement 5 主席兼行政總裁報告 Operation Highlights 8 營運摘要 Management Discussion and Analysis 9 管理層討論及分析 Profiles of Directors and Senior Management 36 董事及高級管理層履歷 Corporate Governance Report 47 企業管治報告 Report of Directors 74 董事會報告 Independent Auditor's Report 108 獨立核數師報告 Consolidated Statement of Profit or Loss 117 綜合損益表 Consolidated Statement of Profit or Loss and Other Comprehensive Income 118 綜合損益及其他全面收益表 Consolidated Statement of ...

Group 1 - The company announced that the Phase II clinical trial for BRIMOCHOL™PF, a candidate drug for presbyopia, enrolled its first patient on March 24, 2025 [1] - The Phase II trial is a multicenter, randomized, double-blind, crossover, and placebo-controlled study aimed at evaluating the efficacy and safety of BRIMOCHOL™PF eye drops in Chinese presbyopia patients, involving 14 centers and a total of 119 patients [1] - On March 21, 2025, the company entered into a distribution and supply agreement with Lunatus Marketing & Consulting FZCO for BRIMOCHOL™PF, granting Lunatus exclusive rights to import, distribute, promote, market, and sell the drug in several Middle Eastern countries [1] Group 2 - On April 8, 2025, the company's partner Tenpoint Therapeutics Ltd. announced the submission of a new drug application for BRIMOCHOLPF to the FDA for the treatment of presbyopia [2] - Tenpoint is a global clinical-stage biotechnology company formed from the merger of Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc., focusing on developing breakthrough therapies to restore vision in aging eyes [2]

Financial Performance - Total revenue for the year ended December 31, 2024, was RMB 69,324,000, compared to RMB 18,750,000 for the year ended December 31, 2023, representing a significant increase of 269%[6]. - Gross profit for the same period was RMB 51,797,000, up from RMB 14,247,000, indicating a growth of 264%[6]. - The adjusted loss for the year was RMB 228,828,000, a reduction from RMB 363,015,000 in the previous year, reflecting an improvement of approximately 37%[7]. - The total comprehensive loss for the year was RMB 156,906,000, compared to RMB 323,931,000 in the previous year, showing a reduction of approximately 51%[6]. - Total revenue for 2024 reached RMB 69.3 million, a year-on-year increase of 268.6% from RMB 18.8 million in 2023, with RMB 32.6 million coming from drug sales[12]. - The company reported a net loss of approximately RMB 237.5 million for the year ended December 31, 2024, compared to a loss of about RMB 385.0 million in 2023, reflecting a reduction of about 38.4%[58]. - The company achieved a milestone payment of RMB 33.5 million from a product licensing agreement, contributing to the increase in revenue[58][59]. - Other income rose slightly to approximately RMB 87.3 million in 2024 from RMB 82.0 million in 2023, primarily due to government subsidies for research and development[63]. Research and Development - The company has made significant progress in developing its innovative product pipeline, with three flagship drug assets in the potential market approval stage[8]. - The Phase III clinical trial for TAB014 was completed in September 2024, with positive topline results expected in January 2025, leading to a submission for a biologics license application[12]. - The NVK002 (low-dose atropine) clinical trials were successfully completed, with significant efficacy and safety results announced in October 2024[19]. - The innovative therapy Cyclosporine A Eye Gel for dry eye syndrome has entered Phase III clinical trials, with patient enrollment underway[12]. - The company is currently conducting several early-stage clinical studies, including BRIMOCHOL™ PF and CARBACHOL™ PF, with expected effective management of R&D expenses[67]. - Research and development expenses decreased to RMB 203.7 million in 2024 from RMB 333.1 million in 2023, reflecting improved operational efficiency[56][66]. - The company plans to invest 200 million HKD in research and development over the next two years to accelerate innovation[162]. Market Expansion and Strategy - The company is strategically expanding its market presence beyond Greater China to selected markets including South Korea, Malaysia, Thailand, Australia, and New Zealand[9]. - The company signed distribution agreements in South Korea, Malaysia, Thailand, Australia, and New Zealand to commercialize BRIMOCHOL™ PF, enhancing its market presence in the Asia-Pacific region[12]. - The company aims to enhance brand visibility and financial stability through the commercialization of more generic drugs[12]. - The company plans to expand the application of ZKY001, a peptide aimed at promoting corneal wound healing, following the approval of its first indication[27]. - The company is preparing to obtain regulatory approval for the eye drops used to treat allergic conjunctivitis (Epinastine Hydrochloride) in the coming months[29]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by 2026[162]. Operational Efficiency - The company achieved a 38.8% reduction in R&D expenses, totaling approximately RMB 203.7 million for the year ending December 31, 2024, compared to RMB 333.1 million in 2023[32]. - General and administrative expenses were approximately RMB 70.8 million for the year ended December 31, 2024, a decrease of about RMB 13.6 million from RMB 84.4 million in 2023[71]. - Sales and distribution expenses increased from RMB 51.9 million in 2023 to approximately RMB 63.5 million in 2024, reflecting increased marketing activities[74]. - The company reported a significant reduction in operational costs by 10% through efficiency improvements in the supply chain[160]. Corporate Governance and Compliance - The company plans to continue evaluating its corporate governance structure to ensure alignment with shareholder interests and compliance with applicable guidelines[138]. - The audit committee has reviewed the annual performance and recommended approval to the board, ensuring compliance with applicable accounting standards and regulations[147]. - The company has strengthened its internal coordination and reporting arrangements for similar transactions to ensure compliance with listing rules[105]. Future Outlook - The company plans to maintain positive momentum and continuous growth through 2025, focusing on clinical programs and brand positioning[49]. - The company anticipates launching innovative drugs with significant efficacy within the next 12 to 24 months, reinforcing its leadership position in the ophthalmic sector[53]. - The company expects to achieve a revenue guidance of 1.5 billion HKD for the next fiscal year, reflecting a projected growth of 25%[160]. - The company is exploring potential acquisitions to strengthen its product portfolio, with a focus on companies specializing in rare diseases[162].

Zhaoke Ophthalmology Limited 兆 科 眼 科 有 限 公 司 (Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands) (於英屬處女群島註冊成立並於開曼群島存續的有限公司) (Stock Code 股份代號 : 6622) NEW REDER IN NO 00 00 00 00 00 000 000 ------------------- N NO OR ON No No Do Do No on on an NOT 200 000 000 No 20 00 00 00 Contents 目錄 Page 頁碼 Corporation Information 2 公司資料 Financial Summary 6 財務概要 Chairman and CEO Statement 8 主席兼行政總裁報告 Management Discussion and Analysis 管理層討論及分析 Overview 13 概覽 Business Rev ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 本 公 告 載 有 前 瞻 性 陳 述，當 中 涉 及 風 險 及 不 明 朗 因 素。除 過 往 事 實 的 陳 述 外， 所 有 陳 述 均 屬 前 瞻 性 陳 述。該 等 陳 述 涉 及 已 知 及 未 知 風 險、不 明 朗 因 素 及 其 他 因 素，當 中 部 分 非 本 公 司 所 能 控 制，可 能 導 致 實 際 業 績、表 現 或 成 果 與 前 瞻 性 陳 述 所 明 示 或 暗 示 者 存 在 重 大 差 異。 閣下不應倚賴前瞻性陳述預測未來事 件。本 公 司 概 不 負 責 更 新 或 修 訂 任 何 前 瞻 性 陳 述，即 使 出 現 新 資 料、未 來 事 件 或 其 他 事 項 亦 然。 Zhaoke Ophthalmology Limited 兆科眼科有限公司 （於英屬處女群島註冊成立並於開曼群島存續的有限公司） ...

Clinical Trials and Regulatory Approvals - NVK002 successfully completed Phase III Mini-CHAMP clinical trial in China, showing strong safety and efficacy as a potential treatment for myopia in children[3] - The company plans to resubmit the NDA for CsA Ophthalmic Gel later this year after addressing regulatory questions[2] - The company expects to make progress with NDA submissions for both 0.01% and 0.02% doses of NVK002 in China, with the CHAMP study anticipated to complete last patient out this summer[5] - The company anticipates starting Phase I and Phase II trials for BRIMOCHOL PF in China, with the completion of the pivotal Phase III study in the U.S. expected this year[5] - TAB014's Phase III clinical trial patient recruitment was completed ahead of schedule, with an NDA submission expected thereafter[16] - The company is focusing on regulatory review for Epinastine after completing its Phase III clinical trial and ANDA filing[5] - The glaucoma product portfolio, comprising seven drugs and one home-use device, is either in ANDA review or at the commercial stage, with Bimatoprost expected to receive approval this year[5] - The company has submitted ANDAs for the majority of its generic glaucoma drugs, with Bimatoprost expected to receive regulatory approval first in 2024[35] - Regulatory approval was received in January 2024 to initiate a clinical trial for BRIMOCHOL PF and Carbachol PF later in 2024[35] - The Phase III clinical trial for NVK002 treatment for myopia completed in August 2023, showing statistically significant efficacy in slowing myopia progression[145] - BRIMOCHOL PF and Carbachol PF received regulatory approval to initiate clinical trials in China in January 2024, targeting presbyopia treatment[145] Financial Performance - The company reported a cash balance of approximately RMB 1.5 billion at the end of 2023, enabling it to pursue key plans and achieve a positive cash flow turning point[6] - For the year ended December 31, 2023, the company recorded a total loss of approximately RMB 385.0 million, a decrease from RMB 407.3 million in 2022, primarily due to first-time sales revenue and increased interest income[40] - The company achieved its first year of revenue with RMB 18.8 million, mainly from sales of its glaucoma drug Bimatoprost Timolol and a Type II medical device for mild dry eye[40] - R&D expenses for the year were approximately RMB 333.1 million, representing an increase of about 12.4% from RMB 296.4 million in 2022, driven by investments in late-stage clinical trials[40] - Selling and distribution expenses rose to approximately RMB 51.9 million in 2023 from RMB 29.9 million in 2022, attributed to an increase in the commercialization team and marketing activities[50] - General and administrative expenses decreased to approximately RMB 84.4 million in 2023 from RMB 86.1 million in 2022, mainly due to a reduction in equity-settled share-based payment expenses[46] - Bank interest income increased significantly to RMB 77.4 million in 2023 from RMB 30.4 million in 2022, benefiting from higher deposit interest rates[42] - The total comprehensive income for the year was a loss of RMB 323.9 million, compared to a loss of RMB 196.4 million in 2022[40] - The company incurred equity-settled share-based payment expenses of RMB 22.0 million in 2023, down from RMB 46.7 million in 2022, indicating a decrease of approximately 52.8%[59] - The non-HKFRS adjusted loss for the year was RMB 363.0 million, slightly higher than the adjusted loss of RMB 360.6 million for the previous year, indicating a marginal increase of approximately 0.1%[59] Market Expansion and Partnerships - The company has established distribution agreements to bring its drugs to South Korea and Malaysia, and is building a presence in Thailand[5] - The company signed an amendment to expand its licensed territories to include multiple regions beyond mainland China, enhancing its market reach[14] - In November 2023, Zhaoke Ophthalmology acquired the commercial rights to Eyprotor from Lee's Pharm to enhance its commercialization capabilities[21] - The company signed a distribution and supply agreement with KDP in March 2023, granting exclusive rights to market NVK002 in South Korea[28] - Zhaoke Ophthalmology plans to establish new licensing partnerships in South Korea, Malaysia, and Thailand in the first quarter of 2024[31] - On March 15, 2024, the company finalized a distribution agreement with TRB Thailand for EyeGiene® reusable eyemasks, expanding its presence in Southeast Asia[32] - In June 2023, the company entered an exclusive agreement with Eyedetec Medical for the Eye Lipid Mobilizer™ in Greater China, South Korea, and ASEAN countries[32] - A strategic partnership was established with Eyebright Medical in August 2023 to jointly develop and commercialize ophthalmic products[32] - The company is actively exploring opportunities in Southeast Asia and evaluating potential activities in Australia following successful out-licensing agreements in South Korea, Malaysia, and Thailand[35] - The company announced its expansion into Malaysia through a distribution agreement for Bimatoprost Timolol eye drops with Pharmaniaga, marking its first overseas distribution deal[171] Research and Development - Zhaoke Ophthalmology's R&D expenses for the year ended December 31, 2023, were RMB333.1 million, reflecting a 12.4% increase from RMB296.4 million in 2022[27] - The R&D team consists of approximately 100 professionals with extensive experience in global biotechnology and pharmaceutical companies[8] - The company is exploring partnership opportunities with leading domestic and international pharmaceutical firms and research institutions[9] - The company aims to leverage its strengths and those of its partners to achieve mutually beneficial goals in the ophthalmology field[10] - The company has made significant progress in its R&D programs, including completing patient enrollment for the TAB014 Phase III trial and ANDA submissions for almost all glaucoma products[107] - The company is focused on enhancing its commercialization capabilities through an omni-channel approach and brand equity improvements[35] - The company is committed to addressing significant unmet medical needs and improving visual health globally despite challenging external conditions[179] Product Launches and Sales - The company launched its first approved drug, Bimatoprost Timolol eye drop, in February 2023, and by the end of 2023, the sales and marketing team had expanded to 71 individuals covering over 1,200 hospitals[21] - The company launched its Bimatoprost Timolol eye drop on JD Health in May 2023, complementing its Tmall flagship store launched in August 2022[21] - The company successfully launched its first pharmaceutical product, Bimatoprost Timolol eye drop, in February 2023, focusing on private hospitals and e-commerce platforms for distribution[145] - Sales of ophthalmic drugs reached RMB 4.736 million, while sales of ophthalmic products totaled RMB 8.414 million for the year ended December 31, 2023[182] - The company generated RMB 5.6 million in revenue from granting exclusive distribution rights for its innovative drug candidate, compared to nil in 2022[40] - Zhaoke Ophthalmology's digital engagement improved in 2023, enhancing online sales on Tmall and JD Health, and building a strong presence on social media platforms[95] - Zhaoke Ophthalmology's WeChat account, Zhaoke Boshi, has grown to over 15,000 followers, establishing a significant online ophthalmologist community[95] Strategic Focus and Future Outlook - The company is focused on expanding its market presence and increasing brand awareness for its first pharmaceutical product, Bimatoprost Timolol eye drop, through various marketing campaigns[70] - The company is committed to rigorous control over cash expenditures and optimizing resource allocation to mitigate financial risks[97] - The company expressed excitement about future possibilities and readiness to face upcoming challenges[98] - The company aims to leverage insights gained from early commercialization efforts to ensure it remains at the forefront of the market[108] - The company is advancing its key clinical programs and expects to move several drugs through the pipeline in the coming years[118] - The company aims to address the significant healthcare demand gap and improve visual health for patients in China and globally[37]

Financial Performance - Total revenue for the year ended December 31, 2023, was RMB 18,750 thousand, with a gross profit of RMB 14,247 thousand[5]. - The net loss for the year was RMB 385,038 thousand, an improvement from a net loss of RMB 407,317 thousand in 2022, showing a reduction of 5.8%[6]. - The adjusted net loss under non-Hong Kong Financial Reporting Standards was RMB 363,015 thousand, slightly higher than RMB 360,633 thousand in the previous year[6]. - For the fiscal year ending December 31, 2023, the company reported revenue of RMB 18,750,000, an increase from the previous year[81]. - The operating loss for the year was RMB 376,567,000, compared to RMB 404,175,000 in the previous year, indicating a reduction in losses[134]. - The basic loss per share was RMB 0.71, slightly improved from RMB 0.75 in the previous year[135]. - The total comprehensive loss for the year was RMB 323,931,000, compared to RMB 196,415,000 in the previous year[159]. - The company recorded a loss of approximately RMB 385.0 million for the year ended December 31, 2023, compared to a loss of approximately RMB 407.3 million for the year ended December 31, 2022, reflecting an improvement[118]. Research and Development - Research and development expenses rose to RMB 333,050 thousand, compared to RMB 296,430 thousand in 2022, indicating an increase of 12.3%[5]. - The company’s R&D expenses for the year were approximately RMB 333.1 million, up 12.4% from RMB 296.4 million in 2022, primarily due to ongoing investments in multiple late-stage clinical trials[82]. - Research and development expenses increased to RMB 333,050,000 from RMB 296,430,000, reflecting ongoing investment in innovation[156]. - The company has ongoing research and development activities for other candidate drugs, with an allocation of RMB 888.86 million, accounting for 46% of the total funds raised[182]. - The company plans to conduct clinical trials for innovative treatments for presbyopia in China in 2024, pending regulatory approval[79]. - The company completed the final patient visit for the small CHAMP trial on August 3, 2023, and announced positive topline results in October 2023, demonstrating strong safety and efficacy for NVK0022 as a potential treatment for childhood myopia[28]. - The FDA accepted the new drug application for NVK002 in June 2023, and the partner Vyluma is advancing the regulatory approval process in the U.S.[29]. - The company submitted simplified new drug applications for five glaucoma generics and one for allergic conjunctivitis, indicating ongoing product development efforts[10]. Market Expansion and Partnerships - The company is focusing on expanding its market presence in selected regions outside Greater China while maintaining its primary focus on the Greater China area[22]. - The company is focused on expanding its presence in the Southeast Asian market through a distribution agreement with TRB Thailand for EyeGiene® reusable eye masks[43]. - The company established a strategic partnership with Aibono to explore opportunities in the ophthalmic product development and commercialization sector[39]. - The company has established a strategic partnership with KDP for the exclusive distribution rights of BRIMOCHOL PF in South Korea[75]. - The company aims to enhance public awareness of eye diseases and treatment solutions, reflecting its commitment to social responsibility[22]. - The company is actively seeking partnerships to enhance its product portfolio and establish more effective sales channels[76]. Financial Position - Total assets as of December 31, 2023, were RMB 2,420,338,000, down from RMB 2,570,623,000 in the previous year[95]. - Cash and cash equivalents at the end of 2023 were approximately RMB 1,461,623,000, a decrease from RMB 1,716,351,000 in 2022[95]. - The company's total net assets decreased to RMB 2,048,318,000 from RMB 2,348,373,000 in the previous year[141]. - The company’s collateralized bank balance was approximately RMB 265.7 million as of December 31, 2023, compared to RMB 172.1 million in 2022, indicating an increase of about 54.4%[98]. - As of December 31, 2023, the company's uncollateralized bank loans amounted to RMB 206.6 million, due within one year or upon demand[97]. - The company aims to optimize resource allocation and control cash expenditures to mitigate financial and business risks from external environments[80]. Employee and Operational Costs - Employee costs increased to RMB 57.206 million from RMB 49.391 million, reflecting the growth in the workforce[55]. - The total employee costs for the year ended December 31, 2023, were approximately RMB 126.8 million, down from RMB 132.1 million in 2022, primarily due to a reduction in share-based payment expenses[131]. - Sales and distribution expenses rose from RMB 29.9 million to approximately RMB 51.9 million, mainly due to an increase in the commercialization team and marketing activities for the product Beimu Sima Tahlor Eye Drops[58]. - The company's total sales and distribution expenses for the year ended December 31, 2023, were RMB 51.9 million, significantly higher than RMB 29.9 million in 2022, representing an increase of about 73.5%[115]. Corporate Governance - The board believes that the current arrangement of having the same person serve as both Chairman and CEO is beneficial for the company and its shareholders[190]. - The board will continue to review the effectiveness of the corporate governance structure to assess the need for separating the roles of Chairman and CEO[190]. - The company is committed to maintaining a high level of corporate governance, which is crucial for its development and safeguarding shareholder interests[190]. - The company has not experienced significant impacts on its performance or financial position due to the new accounting policies introduced during the accounting period[195]. - The consolidated financial statements have been prepared in accordance with all applicable Hong Kong Financial Reporting Standards[194]. Product Development and Sales - The company has established a comprehensive portfolio of innovative and generic products targeting major ophthalmic diseases, including dry eye syndrome and glaucoma[26]. - The company achieved sales of ophthalmic drugs amounting to RMB 4,736 thousand and ophthalmic products amounting to RMB 8,414 thousand for the year ended December 31, 2023[51]. - Exclusive distribution revenue reached RMB 5,600 thousand for the year ended December 31, 2023[51]. - The company has initiated the production of Beimu Sima Tahlor Eye Drops following its approval by the National Medical Products Administration in February 2023[70]. - The new eye gel, administered once daily, aims to significantly improve patient adherence and quality of life[30]. - The new drug application for BRIMOCHOL PF and Carbachol PF was approved by the National Medical Products Administration on January 24, 2024[33].

智通财经APP讯，兆科眼科-B(06622)发布公告，兆科(香港)眼科药物有限公司(兆科眼科有限公司的全资附属公司)与Kwangdong PharmaceuticalCo.,Ltd.(KDP，主要从事药品生产及分销的领先韩国企业)就BRIMOCHOLPF(卡巴可2.75%╱酒石酸溴莫尼丁0.1%固定剂量复方)不含防腐剂外用滴眼液(该产品)订立分销及供应协议。 根据协议条款，公司有权将该产品在大韩民国的独家分销权授予KDP，以代表公司取得药品註册，并独家进口、推广、分销、营销及销售该产品。公司将收取一笔不可退还及不可抵扣的预付款，并可按照若干监管成就及商品销售额获得额外的里程碑付款及特许权使用费。 于2023年4月25日，董事会宣布，公司的合作伙伴-Visus Therapeutics Inc.发表BRIMOCHOLPF用于治疗老花眼的第3期关键BRIO-I试验的正面顶线结果。BRIO-I达到符合美国FDA及欧盟EMA╱英国MHRA预定的主要研究终点，当中展示出以卡巴可及溴莫尼丁单方作为活性对照组，每日一次固定剂量复方BRIMOCHOLPF的元素表现。BRIMOCHOLPF在8小时近距离视力方面具有重大统计显着 ...

Financial Performance - As of June 30, 2023, the group’s current assets amounted to approximately RMB 1,942.4 million, including cash and cash equivalents of about RMB 1,674.7 million[7]. - The total remuneration costs incurred by the group for the six months ended June 30, 2023, were approximately RMB 72.8 million, an increase from approximately RMB 68.9 million for the same period in 2022[14]. - The financial cost increased from approximately RMB 1.3 million for the six months ended June 30, 2022, to approximately RMB 3.6 million for the same period in 2023, primarily due to bank loan interest related to cross-border funding arrangements[1]. - For the six months ending June 30, 2023, R&D expenses reached approximately RMB 205.3 million, an increase of approximately 103.5% from RMB 100.9 million for the same period in 2022[122]. - The company reported a loss before taxation of RMB 233,238,000, compared to a loss of RMB 161,026,000 in the previous year[172]. - Total comprehensive income for the period was a loss of RMB 135,031,000, compared to a loss of RMB 46,362,000 in the same period of 2022[172]. - As of June 30, 2023, the company reported revenue of RMB 11,304,000, with a gross profit of RMB 10,154,000[172]. - Other income for the period was RMB 39,523,000, compared to RMB 11,866,000 in the same period of 2022[172]. Research and Development - The company’s R&D team comprised approximately 100 professionals at the end of the reporting period, led by an international management team with extensive industry experience[20]. - The treatment for myopia progression control, NVK002, completed its one-year Phase III bridging trial in early August 2023, with patient recruitment for TAB014 expected to complete by the end of this year[19]. - The company is preparing for the Phase III clinical trial of another self-developed innovative asset, ZKY001[19]. - The company has filed multiple ANDA submissions for its generic assets, addressing unmet ophthalmic medical needs in China[33]. - The company has filed 2 additional ANDA submissions to the NMPA for Travoprost and Travoprost Timolol, indicating ongoing efforts in drug development[158]. - The continuing R&D activities for other key drug candidates utilized approximately HK$ 888.86 million, accounting for 46.00% of the total expected net proceeds[119]. - R&D activities for innovative and generic drug candidates utilized approximately HK$ 57.97 million, representing 3.00% of the total expected net proceeds[119]. - Zhaoke Ophthalmology is progressing its R&D efforts, with a new drug application for Cyclosporine A eye gel under review and multiple clinical projects in late-stage development[142]. Product Development and Commercialization - Zhaoke Ophthalmology's Bimatoprost Timolol eye drop (晶贝莹®) received marketing authorization from the NMPA in February 2023, with the first prescription issued on March 8, 2023[36][44]. - The company aims to enhance brand recognition through the commercialization of its first approved drug, which will support future innovative drug launches[36]. - The eye drop product is now available on JD Health, increasing accessibility for glaucoma patients[36]. - Zhaoke Ophthalmology launched its first commercialized drug, Bimatoprost Timolol eye drop, in May 2023 on JD Health, enhancing patient access to its products[137]. - The company has commercialized two products on Tmall: the heat compress eyepatch for mild dry eye disease in August 2022 and the Far Infrared Eye Heat Compress eyepatch in March 2023, expanding its product line[134]. Strategic Partnerships and Agreements - A strategic partnership was established with Aibono to explore opportunities in research, development, and commercialization of ophthalmic products[28]. - An exclusive licensing, supply, and distribution agreement was signed with Eyedetec Medical for the Eye Lipid Mobilizer™ in Greater China and several Southeast Asian countries[32]. - In March 2023, the company signed a distribution agreement with KDP for exclusive rights to market NVK002 in South Korea, including upfront and milestone payments[122]. - In June 2023, an exclusive license and distribution agreement was established with Eyedetec Medical for the Eye Lipid Mobilizer™ in Greater China and Southeast Asia[124]. - A strategic partnership was formed with Eyebright Medical in August 2023 to explore R&D and commercialization of ophthalmic products[125]. Share Options and Capital Structure - The Pre-IPO Share Option Scheme allows for the issuance of up to 45,732,000 shares, representing approximately 8.41% of the total issued share capital of 543,843,992 shares as of June 30, 2023[58]. - The company conditionally granted a total of 45,732,000 options to 109 grantees under the Pre-IPO Share Option Scheme, which represents approximately 8.41% of the total issued share capital as of June 30, 2023[77]. - The exercise price of the options granted under the Pre-IPO Share Option Scheme ranges from US$0.09 to US$1.14 per share[77]. - The Post-IPO Share Option Scheme was conditionally approved on April 1, 2021, allowing for a maximum of 53,515,550 shares to be issued, representing approximately 9.84% of the total issued share capital as of June 30, 2023[81]. - The total issued share capital of the company as of June 30, 2023, was 543,843,992 shares[71]. - The company has adopted two share option schemes that require disclosure under the Listing Rules[73]. - As of June 30, 2023, the number of options available for future grant under the Post-IPO Share Option Scheme was 45,695,550[110]. - The total number of outstanding options as of June 30, 2023, is 5,940,000 shares[100]. Financial Position and Assets - As of June 30, 2023, non-current assets amounted to RMB 594,951,000, a slight decrease from RMB 597,876,000 as of December 31, 2022[192]. - Current assets totaled RMB 1,942,415,000, compared to RMB 1,972,747,000 at the end of 2022, indicating a decrease in liquidity[192]. - Net current assets increased to RMB 1,778,207,000 from RMB 1,661,033,000, reflecting improved short-term financial health[192]. - Total assets less current liabilities were RMB 2,255,984,000, down from RMB 2,376,083,000, showing a decline in overall asset value[192]. - Non-current liabilities, including lease liabilities, were reported at RMB 26,390,000, a decrease from RMB 27,703,000[194]. - Total equity stood at RMB 2,229,594,000, down from RMB 2,348,373,000, indicating a reduction in shareholder equity[194]. - Cash and cash equivalents increased to RMB 1,716,351,000 from RMB 1,674,729,000, suggesting a positive cash flow situation[192]. - Trade and other payables rose to RMB 108,395,000 from RMB 83,418,000, indicating increased obligations[192]. - The company reported inventories of RMB 4,068,000, reflecting a new addition to current assets[192]. Corporate Governance and Compliance - The Audit Committee reviewed the interim financial report for the six months ended June 30, 2023, ensuring compliance with accounting standards[165]. - The interim financial report is unaudited, highlighting the need for caution in interpreting the figures presented[191]. - The company believes the current arrangement of having the same individual serve as both Chairman and CEO is beneficial and does not harm the balance of power[96]. - The company has not been involved in any material litigation or arbitration during the six months ended June 30, 2023[145]. - There were no significant events affecting the group after the reporting period up to the date of the report[91]. - The company does not recommend the distribution of an interim dividend for the six months ended June 30, 2023[92]. - The company did not declare an interim dividend for the six months ending June 30, 2023[126].